XNK Therapeutics Competitors and Similar CompaniesClear all
XNK Therapeutics's competitors and similar companies include Pharmstandard, Agios Pharmaceuticals, Debiopharm and TriSalus Life Sciences.
 XNK Therapeutics XNK Therapeutics (formerly CellProtect Nordic Pharmaceuticals) is a pharmaceutical company developing cell-based therapies for the treatment of severe diseases. |  Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products. |  Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. |  Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections. |  TriSalus Life Sciences TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors. | |
Founding Date | Founding Date 2013 | Founding Date 2003 | Founding Date 2008 | Founding Date 1979 | Founding Date 2009 |
Type | Type Private | Type Subsidiary | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Huddinge, SE HQ | Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Petrovo Dalnee, RU Tomsk, RU Ufa, RU Vol'ginskii, RU | Locations Cambridge, US HQ | Locations Lausanne, CH HQ Oss, NL | Locations Westminster, US HQ Bannockburn, US Cranston, US |
Employees | Employees 9 | Employees 1,77814% increase | Employees 53611% increase | Employees 4771% decrease | Employees 106 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 2.7 b | Valuation ($) N/A | Valuation ($) 117.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ₽152.1b (FY, 2024) | Revenue (est.) $54m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $45.2m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods ₽117b (FY, 2024) | Cost of goods $6.3m (FY, 2025) | Cost of goods N/A | Cost of goods $7m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ₽35.2b (FY, 2024) | Gross profit $47.7m (FY, 2025) | Gross profit N/A | Gross profit $38.2m (FY, 2025) |
Net income | Net income N/A | Net income ₽22.7b (FY, 2024) | Net income ($412.8m) (FY, 2025) | Net income N/A | Net income ($39.2m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 2.1m | Total funding raised $ 52.2m |
For sources of this data, please see the company profile
View Company Profiles
Pharmstandard
HQ
Dolgoprudny, RU
Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.
View companyAgios Pharmaceuticals
HQ
Cambridge, US
Employees
536↑ 11% increase
Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.
View companyDebiopharm
HQ
Lausanne, CH
Employees
477↓ 1% decrease
Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections.
View companyTriSalus Life Sciences
HQ
Westminster, US
Employees
106
TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors.
View company